ID: ALA378729

Max Phase: Preclinical

Molecular Formula: C22H17N3O6S

Molecular Weight: 451.46

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC1=NN(c2ccc(S(N)(=O)=O)cc2)C(=O)/C1=C\c1ccc(-c2ccccc2C(=O)O)o1

Standard InChI:  InChI=1S/C22H17N3O6S/c1-13-19(21(26)25(24-13)14-6-9-16(10-7-14)32(23,29)30)12-15-8-11-20(31-15)17-4-2-3-5-18(17)22(27)28/h2-12H,1H3,(H,27,28)(H2,23,29,30)/b19-12-

Standard InChI Key:  MFAUPOYGLDVFKL-UNOMPAQXSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 451.46

Molecular Weight (Monoisotopic): 451.0838

AlogP: 3.10

#Rotatable Bonds: 5

Polar Surface Area: 143.27

Molecular Species: ACID

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.33

CX Basic pKa:

CX LogP: 2.47

CX LogD: -0.95

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.57

Np Likeness Score: -1.45

References

1. Dayam R, Aiello F, Deng J, Wu Y, Garofalo A, Chen X, Neamati N..  (2006)  Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents.,  49  (15): [PMID:16854058] [10.1021/jm051296s]

Source

Source(1):

• Scientific Literature